Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Opioid Use Disorder: early-phase trial registry
156 of 258 indexed Opioid Use Disorder trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #40 of 28,707 conditions by registered trial count.
258 US clinical trials · 156 currently recruiting · #40 of 28,707 conditions by registered trial count
Opioid Use Disorder: 258 US clinical trials tracked, 156 recruiting.
Opioid Use Disorder is the subject of 258 registered US clinical trials on ClinicalTrials.gov, 156 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 59 in Phase 1-2 (earlier-stage). The most active sponsor is Yale University, running 19 of these trials.
Enrollment posture brief
Registry condition opioid-use-disorder
OPEN 156 | RECR 60% | LATE 23 | EARLY 59 | RANK #40 | SPON 19
Volume-matched condition peers
Nearest open-share peer: HIV Prevention (61% recruiting · 33 trials)
Opioid Use Disorder lists 156 open slots (60% of 258 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Opioid Use Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Opioid Use Disorder is recruiting above its size-band peers.
156 of 258 indexed trials (60.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Opioid Use Disorder trials is spread across many organizations.
Yale University accounts for 19 of 258 trials (7.4%). 127 distinct sponsors appear on at least one study for this condition label.
-
Typical Opioid Use Disorder enrolment sits around 103 participants.
Median target enrolment is 103 among the 258 trials that report a genuine target (sentinel values excluded). 121 of those (46.9%) plan for fewer than 100 participants.
-
Opioid Use Disorder research is mostly interventional.
233 interventional and 25 observational studies make up this index (90.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
258 total, page 2 of 6
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
University of New Mexi
NCT06565416
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
University of Pennsylvania
NCT04480554
Smartphones for Opiate Addiction Recovery
NYU Langone Health
NCT05033028
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
Rutgers, The State University of New Jersey
NCT06642181
Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment
Geisinger Clinic
NCT07197801
KIOS Mobile App Evaluation
The University of Texas Health Science Center at San Antonio
NCT06212557
Stepped Care for Patients to Optimize Whole Recovery
Yale University
NCT05155163
Pain Self-Management and Treatment Engagement for Patients Taking Opioids
University of Pittsburgh
NCT06855732
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
University of Alabama at Birmingham
NCT06104280
Assessing Optimal XRB Initiation Points in Jail
NYU Langone Health
NCT06051890
GLP-1R Agonist Treatment for Opioid Use Disorder
Milton S. Hershey Medical Center
NCT06548490
Integrating Brain, Neurocognitive, and Computational Tools in OUD
University of Pennsylvania
NCT06136247
A Bundled Intervention
University of Alabama at Birmingham
NCT06593093
Adversity, Brain and Opioid Use Study
University of Michigan
NCT06355778
Addressing Racial Disparities in Opioid Overdose Using Peer Recovery Coach Training and mHealth Platform
Friends Research Institute
NCT06573476
Opioid Use Disorder and Pain
Yale University
NCT06800703
IMPOWR-ME Project 1: Trial of Yoga and Physical Therapy Onsite at Opioid Treatment Programs
Albert Einstein College of Medicine
NCT05492825
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
New York State Psychiatric Institute
NCT05011266
Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder
University of Minnesota
NCT07158853
Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment
Albert Einstein College of Medicine
NCT05039554
Divided or Single Exposure (DOSE) Study
University of Maryland, Baltimore
NCT05459402
The Youth Opioid Recovery Support (YORS) Intervention
Potomac Health Foundations
NCT04173416
Combined THC and CBD for OUD and Chronic Pain
Yale University
NCT06544291
High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)
Rutgers, The State University of New Jersey
NCT05589181
Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation
Washington State University
NCT05733442
Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD
University of Vermont
NCT06288711
Towards Testing the Effectiveness of Recovery Community Centers (RCCs)
Massachusetts General Hospital
NCT07010978
Optimization of NIBS for Treatment of Addiction
Case Western Reserve University
NCT04379115
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
Johns Hopkins University
NCT05145764
Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms
Vanderbilt University Medical Center
NCT05142267
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
NCT04360681
The Effect of Light Intervention on Recovery in Individuals With Opioid Use Disorder (OUD)
University of Alabama at Birmingham
NCT06832007
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Emory University
NCT05834478
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
Boston Medical Center
NCT06732596
Remotely Observed Methadone Evaluation II
Sonara Health
NCT06338280
Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy
Ilana Hull
NCT05942313
Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery
Jenna-Leigh Wilson
NCT06949826
tDCS to Decrease Opioid Relapse (UH3)
Butler Hospital
NCT06432465
Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects
Virginia Commonwealth University
NCT06981195
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Yale University
NCT01730781
Improving Social Connectedness Through Digital Health to Enhance Recovery from OUD Among the Justice Involved Population
Rhode Island Hospital
NCT06896656
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Johns Hopkins University
NCT06067737
Developing a Clinical Outcome Assessment for Opioid Craving
Johns Hopkins University
NCT05109429
Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD Adherence to Adolescents With OUD
Potomac Health Foundations
NCT06774248
Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD
Ohio State University
NCT06718491
OUD (Opioid Use Disorder) Target Trial
Duke University
NCT06585709
Integrated Treatment for Opioid Use Disorder and PTSD
Medical University of South Carolina
NCT06641115
Aim 2 - Conversations Can Save Lives: TALKing About Buprenorphine & Methadone for Opioid Use Treatment Initiation
Baystate Medical Center
NCT06527820
Infectious Disease (ID) Testing OUtreach in Carceral Hubs
Boston Medical Center
NCT06679751
Low-dose Buprenorphine Initiation for Opioid Use Disorder
Montefiore Medical Center
NCT05450718
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 27 |
| Phase 2 | 32 |
| Phase 3 | 12 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Opioid Use Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Opioid Use Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Opioid Use Disorder page
258 registered trials, 156 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 156 Opioid Use Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Yale University sponsors the most Opioid Use Disorder trials on record, review their full trial history before evaluating a specific study. See Yale University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Opioid Use Disorder condition card totals 258 registered trials; most-linked intervention Placebo; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.